CareDx Raises 2026 Revenue Guide to $490–$500M, Stock Jumps 16%
CDNA has more than doubled off its 52-week low of $11.259 on elevated volume (3.0× avg).
Summary
CareDx raised its full-year 2026 revenue guidance to $490–$500 million, up from prior expectations, following a 52% surge in Q2 revenue to $131.9 million. The stock jumped ~16% to $44.14, reflecting strong market reaction. This follows the July 30 earnings release and guidance raise, now with the specific range disclosed. The company also granted 15,822 restricted stock units to a new executive as an inducement, signaling continued investment in leadership. With the recent Medicare LCD confirmation and the Naveris acquisition closing, the raised outlook underscores accelerating momentum in transplant diagnostics.
At the time of this announcement, CDNA was trading at $42.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $11.26 to $45.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.